Prostate Cancer: To Screen or Not to Screen?

Urologic Clinics of North America

Volumn 37, Issue 1, 2010, Pages 1-9

  Shteynshlyuger, Alex ^a   Andriole, Gerald L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ERSPC trial; PLCO trial; Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ANXIETY; BRACHYTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEFECATION DISORDER; DEPRESSION; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; DISEASE SEVERITY; GLEASON SCORE; HUMAN; LIFE EXPECTANCY; MALE; MASS SCREENING; METASTASIS POTENTIAL; MICTURITION DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY AND SPECIFICITY; SEXUAL DYSFUNCTION; TRANSRECTAL ULTRASONOGRAPHY; WATCHFUL WAITING;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COST OF ILLNESS; DIGITAL RECTAL EXAMINATION; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK FACTORS;

EID: 75449091230     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2009.11.004     Document Type: Review

References (33)

1. Barry M.J. Screening for prostate cancer-the controversy that refuses to die. N Engl J Med 360 13 (2009) 1351-1354
2. Holmberg L. Prostate cancer screening: the need for problem-solving that puts men's interests first. Eur Urol 56 1 (2009) 34-37
3. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 149 3 (2008) 185-191
4. Andriole G.L., Crawford E.D., Grubb III R.L., et al. PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360 13 (2009) 1310-1319 Erratum in: N Engl J Med 2009 Apr 23;360(17):1797
5. Schröder F.H., Hugosson J., Roobol M.J., et al. ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 13 (2009) 1320-1328
6. Horner MJ, Ries LAG, Krapcho M, et al, editors. SEER Cancer statistics review, 1975-2006. Bethesda (MD): National Cancer Institute. Table 23.9: cancer of the prostate. Available at: http://seer.cancer.gov/csr/1975_2006/index.html. Accessed October 15, 2009.
7. Hugosson J., Aus G., Becker C., et al. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU Int 85 9 (2000) 1078-1084
8. Bill-Axelson A., Holmberg L., Filén F., et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100 16 (2008) 1144-1154
9. Lev E.L., Eller L.S., Gejerman G., et al. Quality of life of men treated for localized prostate cancer: outcomes at 6 and 12 months. Support Care Cancer 17 5 (2009) 509-517
10. Couper J.W., Love A.W., Dunai J.V., et al. The psychological aftermath of prostate cancer treatment choices: a comparison of depression, anxiety and quality of life outcomes over the 12 months following diagnosis. Med J Aust 190 suppl 7 (2009) S86-S89
11. Litwin M.S., Hays R.D., Fink A., et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 273 2 (1995) 129-135
12. Litwin M.S., Gore J.L., Kwan L., et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 109 11 (2007) 2239-2247
13. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 12 (2008) 1250-1261
14. Johansson E., Bill-Axelson A., Holmberg L., et al. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol 55 2 (2009) 422-430
15. Draisma G., Etzioni R., Tsodikov A., et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101 6 (2009) 374-383
16. Welch H.G., and Albertsen P.C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 101 19 (2009) 1325-1329
17. Okotie O.T., Roehl K.A., Han M., et al. Characteristics of prostate cancer detected by digital rectal examination only. Urology 70 6 (2007) 1117-1120
18. Gosselaar C., Roobol M.J., Roemeling S., et al. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol 54 3 (2008) 581-588
19. Thompson I.M., Ernst J.J., Gangai M.P., et al. Adenocarcinoma of the prostate: results of routine urological screening. J Urol 132 4 (1984) 690-692
20. Philip J., Hanchanale V., Foster C.S., et al. Importance of peripheral biopsies in maximizing the detection of early prostate cancer in repeat 12-core biopsy protocols. BJU Int 98 3 (2006) 559-562
21. Pepe P., and Aragona F. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 70 6 (2007) 1131-1135
22. Jones J.S., Patel A., Schoenfield L., et al. Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J Urol 175 2 (2006) 485-488
23. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 1 (2005) 66-70
24. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350 22 (2004) 2239-2246
25. Raaijmakers R., Kirkels W.J., Roobol M.J., et al. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 60 5 (2002) 826-830
26. Djavan B., Waldert M., Zlotta A., et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study [review]. J Urol 166 3 (2001) 856-860
27. Haas G.P., Delongchamps N.B., Jones R.F., et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 99 19 (2007) 1484-1489
28. Seitz M., Gratzke C., Schlenker B., et al. Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer. Urol Oncol (2009) [Epub ahead of print]
29. Shimizu T., Nishie A., Ro T., et al. Prostate cancer detection: the value of performing an MRI before a biopsy. Acta Radiol 50 9 (2009) 1080-1088
30. Boyle P., and Brawley O.W. Prostate cancer: current evidence weighs against population screening. CA Cancer J Clin 59 4 (2009) 220-224
31. U.S. Census. Bureau, statistical abstract of the United States: 2009. (128th edition) (2008). http://www.census.gov/compendia/statab/tables/09s0103.pdf Accessed October 10, 2009
32. Nguyen P.L., Chen M.H., Renshaw A.A., et al. Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations. Int J Radiat Oncol Biol Phys (2009) [Epub ahead of print]
33. Shappley III W.V., Kenfield S.A., Kasperzyk J.L., et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 27 30 (2009) 4980-4985